Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.

Skapinakis P, Caldwell DM, Hollingworth W, Bryden P, Fineberg NA, Salkovskis P, Welton NJ, Baxter H, Kessler D, Churchill R, Lewis G.

Lancet Psychiatry. 2016 Aug;3(8):730-9. doi: 10.1016/S2215-0366(16)30069-4. Epub 2016 Jun 16.

2.

Managing obsessive compulsive disorder.

Brakoulias V.

Aust Prescr. 2015 Aug;38(4):121-3. Epub 2015 Aug 3. Review.

3.

Assessment and management of treatment-refractory obsessive-compulsive disorder in children.

Bloch MH, Storch EA.

J Am Acad Child Adolesc Psychiatry. 2015 Apr;54(4):251-62. doi: 10.1016/j.jaac.2015.01.011. Epub 2015 Jan 30. Review.

4.

Management of obsessive-compulsive disorder.

Seibell PJ, Hollander E.

F1000Prime Rep. 2014 Aug 1;6:68. doi: 10.12703/P6-68. eCollection 2014. Review.

5.

Pharmacological treatment of obsessive-compulsive disorder.

Pittenger C, Bloch MH.

Psychiatr Clin North Am. 2014 Sep;37(3):375-91. doi: 10.1016/j.psc.2014.05.006. Epub 2014 Jul 24. Review.

6.

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University, Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O'Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR.

BMC Psychiatry. 2014;14 Suppl 1:S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2. Review.

7.

Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report.

De Berardis D, Serroni N, Marini S, Martinotti G, Ferri F, Callista G, La Rovere R, Moschetta FS, Di Giannantonio M.

Case Rep Psychiatry. 2012;2012:642752. doi: 10.1155/2012/642752. Epub 2012 Oct 9.

8.

Obsessive compulsive disorder.

Soomro GM.

BMJ Clin Evid. 2012 Jan 18;2012. pii: 1004. Review.

9.

Pharmacotherapy of anxiety disorders: a critical review.

Koen N, Stein DJ.

Dialogues Clin Neurosci. 2011;13(4):423-37. Review.

10.

Sleep and anxiety disorders.

Staner L.

Dialogues Clin Neurosci. 2003 Sep;5(3):249-58.

11.

Psychotherapy and medication management strategies for obsessive-compulsive disorder.

Walsh KH, McDougle CJ.

Neuropsychiatr Dis Treat. 2011;7:485-94. doi: 10.2147/NDT.S13205. Epub 2011 Aug 23.

12.

Still Struggling: characteristics of youth with OCD who are partial responders to medication treatment.

Freeman J, Sapyta J, Garcia A, Fitzgerald D, Khanna M, Choate-Summers M, Moore P, Chrisman A, Haff N, Naeem A, March J, Franklin M.

Child Psychiatry Hum Dev. 2011 Aug;42(4):424-41. doi: 10.1007/s10578-011-0227-4.

13.

Monoamine transporters: vulnerable and vital doorkeepers.

Lin Z, Canales JJ, Björgvinsson T, Thomsen M, Qu H, Liu QR, Torres GE, Caine SB.

Prog Mol Biol Transl Sci. 2011;98:1-46. doi: 10.1016/B978-0-12-385506-0.00001-6. Review.

14.

Current trends in drug treatment of obsessive-compulsive disorder.

Decloedt EH, Stein DJ.

Neuropsychiatr Dis Treat. 2010 May 25;6:233-42.

15.

High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.

Cleveland WL, DeLaPaz RL, Fawwaz RA, Challop RS.

Neural Plast. 2009;2009:768398. doi: 10.1155/2009/768398. Epub 2010 Feb 18.

16.

Management of obsessive-compulsive disorder with fluvoxamine extended release.

Ordacgi L, Mendlowicz MV, Fontenelle LF.

Neuropsychiatr Dis Treat. 2009;5:301-8. Epub 2009 Jun 10.

17.

An emerging role for escitalopram in the treatment of obsessive-compulsive disorder.

Hedges DW, Woon FL.

Neuropsychiatr Dis Treat. 2007 Aug;3(4):455-61.

Items per page

Supplemental Content

Write to the Help Desk